The clinical significance of the association of PGRMC1 with proliferation includes the ongoing investigations into why one arm of the Women’s Health Initiative, including women treated with combination estrogen/progestin, had an increased risk for developing breast cancer versus the estrogen-only arm (93). Here, PGRMC1 is linked to breast carcinoma.